AstraZeneca's Type-2 Diabetes Drug Qtrilmet Approved in the EU
November 15 2019 - 2:41AM
Dow Jones News
By Adriano Marchese
AstraZeneca PLC (AZN.LN) said Friday that its Qtrilmet drug has
been approved in the European Union to treat type-2 diabetes.
The drug maker said that Qtrilmet, a modified-release tablet to
improve glycaemic control in adults with type-2 diabetes, was
approved by the European Commission, based on data from five Phase
3 trials.
The drug was approved in the U.S. in May under the name Qternmet
XR.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 15, 2019 02:26 ET (07:26 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Sep 2024 to Oct 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Oct 2023 to Oct 2024